GLP-1
There are hundreds, even thousands of biotech and pharmaceutical companies.
As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
The company’s demise was explained in a blog post by Atlas Venture partner Bruce Booth.
After falling short of analysts’ expectations in its latest quarter, Novo Nordisk is restructuring its commercial operations as it looks to fend off challenges to its products.
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
This data will be presented by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
PRESS RELEASES